Overview of the drug development pipeline for presbyopia
Refractive error is an issue with focusing light precisely onto the retina because of the state of the eye. The common types of refractive errors are hyperopia, astigmatism, and presbyopia. Refractive errors such as myopia, hyperopia, astigmatism, and presbyopia often occur in people aging between 40 and 50 years. According to the CDC, in 2015, around 11 million people can improve their vision through proper refractive error correction. Presbyopia is the progressive loss of eyes capacity to focus around close-by objects. The disease occurs due to hardening of the lens of the eye, causing the eye to focus light behind rather than on the retina when looking at close objects. It becomes tough to focus while reading, working on a computer, or using a mobile phone due to presbyopia. Technavio’s market research analysis suggests that as presbyopia gets mostly noticeable at the age of mid-40s, the increasing number of the aging population across the globe is likely to promote the drug development for presbyopia in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of presbyopia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development for presbyopia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- ALLERGAN
- Janssen
- Novartis
- Presbyopia Therapies
Therapeutic assessment of the drug development pipeline for presbyopia by route of administration
- Topical
- Unknown
The topical route of administration (ROA) involves the application of the drug to a space on or in the body, which will have a more direct effect on the target cells. Most often topical administration means the application to the body surface such as the skin or mucous membranes.
Therapeutic assessment of the drug development pipeline for presbyopia by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for presbyopia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for presbyopia?
- What are the companies that are currently involved in the drug development for presbyopia?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.